Patients with refractory metastatic colorectal cancer experience survival benefits with fruquintinib
Researchers from Â鶹ӳ» MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer. Findings from the global FRESCO-2 trial, published today in The Lancet, were first presented at the European Society for Medical Oncology (ESMO) Congress 2022.
HER2-low metastatic breast cancer patients report preserved quality of life with trastuzumab deruxtecan treatment
Ìý
ABSTRACT 2170O
Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2...